Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Hideaki Okada, MD"'
Autor:
Motoko Tachihara, MD, PhD, Akito Hata, MD, Takaaki Tokito, MD, PhD, Satoshi Hara, MD, PhD, Hideaki Okada, MD, Satoru Miura, MD, PhD, Yuki Sato, MD, Eriko Tabata, MD, PhD, Hiroshi Watanabe, MD, PhD, Yusuke Takayama, MD, PhD, Ryo Toyozawa, MD, PhD, Keiichi Ota, MD, PhD, Kazushige Wakuda, MD, PhD, Atsushi Nakamura, MD, PhD, Mototsugu Shimokawa, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100569- (2023)
Introduction: Docetaxel plus ramucirumab could be a promising treatment for chemo-naive elderly patients with NSCLC, but high incidence of febrile neutropenia (FN) is a critical concern. We thus adopted a routine primary prophylactic pegylated-granul
Externí odkaz:
https://doaj.org/article/8ba5db23f12745978f3d1100137cfd60
Autor:
Taira Ninomaru, MD, Hideaki Okada, MD, Mika Fujishima, MD, PhD, Kei Irie, PhD, Shoji Fukushima, PhD, Akito Hata, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100145- (2021)
The spread of next-generation sequencing enables clinicians to identify rare oncogene alterations, including MET exon 14 skipping mutation, in clinical practice for NSCLC. Several tyrosine kinase inhibitors for MET exon 14 skipping mutation such as c
Externí odkaz:
https://doaj.org/article/1ecf4d948d4f4e88a0c38703ea02140e